|
|
Pharma 40
We present 2011’s top 40 most
influential people in the industry,
as judged by our panel of industry
experts. Editor Elly Earls takes
stock of the ups and downs in
what has been an eventful year.
view pdf
|
Parkinson’s disease: a novel approach
GlobalData reveals how novel
targeted therapies such as fetal
cell transplantation, stem cells and
gene therapy hold the promise of
a cure for Parkinson’s disease. view pdf
|
|
Life sciences reshaped
Adapting to the most recent
financial downturn could see
a significant change in the life
sciences industries in the long
term, according to a survey of
the sector’s executives. view pdf
|
Patent is a virtue
The pharmaceutical industry is one
of the largest contributors to the
global economy, to R&D and to
improving health. However, its
patent framework needs to be
further explored and better aligned
to provide cost-effective healthcare
globally, writes Mian Atif Saeed,
Bristol-Myers Squibb. view pdf
|
A tale of two structures
US healthcare reform is not the
only complication for the North
American drugs industry.
Cross-border trade with Canada
adds a further challenge.
Chris Ward, PhRMA’s deputy vice
president for international alliance
development, believes the answer
lies in innovation.
view pdf
|
|
The right ingredients
The European Directorate for the
Quality of Medicines has suspended
a number of certificates for active
pharmaceutical ingredients. As
regulations are amended, and
manufacturers alter their processes
to become more cost-effective pharma consultant
Dr Pauline
McGregor looks at how they can
continue to satisfy regulations. view pdf
|
Mutually beneficial
Combination drugs are becoming increasingly important
to pharmaceutical companies; but developing and
bringing them to market is far from easy. Fangdong
Yin, Eli Lilly, discusses how to overcome the
challenges. view
pdf
|
Look, indicate, manoeuvre
The MARCAR project is a
groundbreaking study of how
biomarkers can be used to predict
the effects of non-genotoxic
carcinogens. Scientific coordinator
Roland Wolf explains what its
findings mean for animal testing
and our understanding of cancer. view pdf
|
|
What makes the perfect match?
Risk associated with developing
pharmaceutical products and
managing their intellectual property
rights may be better managed
in-house, but a partnership can
be beneficial, too. Peter Murray
explains what’s involved in
becoming a sponsoring company.
view pdf
|
Back to basics
As manufacturing models evolve to
embrace quality by design and
process analytical technology,
pharmaceutical companies
have had to start reassessing their
IT systems to maximise efficiencies.
For Tom Van Laar, head of global
technical operations at Novartis, the
only way forward is to integrate IT
into companies’ business processes
view pdf
What’s the buzz about PAT?
Process Analytical Technology is a
topic of much debate, but what is it
exactly? Why should businesses
implement it and what benefits
does it offer? Peter Amanatides,
Noven Pharma, explains.
view pdf
|
Face the risks
Risk management is crucial for an
efficient supply chain, believes
Viliam Kovac, Roche Diagnostics.
Creating a suitable mindset might
be the right place to start. view pdf
Flight of fancy
Consultation is underway on
the pre-screening of cargo for
explosives on all flights entering the
US. Doug Brittin of the TSA outlines
the implications of the legislation. view pdf
Hot topic for the cold chain
Lab testing of pharmaceutical cold
packaging can reduce risk and costs,
says Kirsten Heddema-Kaptein of
the Topa Institute for Packaging
and Distribution. view pdf
Identify and authenticate
Jean-Marc Bobée, sanofi-aventis,
and Tassilo Korab, Healthcare
Compliance Packaging Council,
explain how a new European
directive will tighten the net on
counterfeit pharmaceuticals. view pdf |
|
Open the treasure chest
Huge pressure is being placed on
the pharmaceutical industry to
develop more complex drugs. But
no organisation can do this on its
own. Dr Paul Stoffels, Johnson &
Johnson, believes collaboration
between Big Pharma, biotech and
academic institutions is key. view pdf
|
|
|
